This Fact Sheet informs you of the significant known and potential risks and benefits of the emergency use of the Ellume COVID-19 Home Test.

The Ellume COVID-19 Home Test is a rapid, lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid antigens.

This test is authorized for non-prescription home use with self-collected direct mid-turbinate nasal swab specimens from individuals aged 16 years or older with symptoms of COVID-19 within the first 7 days of symptom onset. This test is also authorized for non-prescription home use with adult-collected mid-turbinate nasal swab specimens from individuals aged 2 years or older with symptoms of COVID-19 within the first 7 days of symptom onset.

This test is authorized for non-prescription home use with self-collected mid-turbinate nasal swab specimens from individuals aged 16 years or older, or adult-collected mid-turbinate nasal swab specimens from individuals aged 2 years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two to three days with at least 24 hours (and no more than 48 hours) between tests.

The Ellume COVID-19 Home Test does not differentiate between SARS-CoV and SARS-CoV-2.

All individuals whose specimens are tested with this assay will have received the Ellume COVID-19 Home Test Product Information Leaflet (PIL).

What are the symptoms of COVID-19?

Many patients with COVID-19 develop fever and/or symptoms of acute respiratory illness (e.g. cough, dyspnea), although some individuals experience only mild symptoms or no symptoms at all. The current information available to characterize the spectrum of clinical illness associated with COVID-19 suggests that, when present, symptoms include cough, shortness of breath or dyspnea, fever, chills, myalgias, headache, sore throat, new loss of taste or smell, nausea or vomiting or diarrhea. Signs and symptoms may appear any time from 2 to 14 days after exposure to the virus, and the median time to symptom onset is approximately 5 days. For further information on the symptoms of COVID-19 please see the link provided in “Where can I go for updates and more information?” section.

Public health officials have identified cases of COVID-19 throughout the world, including the United States. Please check the CDC COVID-19 webpage (see link provided in “Where can I go for updates and more information?” section) or your local jurisdiction’s website for the most up to date information.

This test is to be performed only using mid-turbinate nasal swab specimens self-collected by an individual aged 16 years or older, or mid-turbinate nasal swab specimens collected by an adult from any individual (≥2 years old) within the first seven days of symptom onset or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours (and no more than 48 hours) between tests.

What do I need to know about COVID-19 testing?

Current information on COVID-19 for healthcare professionals is available at CDC’s webpage, information for healthcare professionals (see links provided in “Where can I go for updates and more information?” section).

- The Ellume COVID-19 Home Test is authorized for non-prescription home use with self-collected mid-turbinate nasal swab specimens from individuals aged 16 years or older with symptoms of COVID-19 within the first 7 days of symptom onset.

- The Ellume COVID-19 Home Test is also authorized for non-prescription home use with adult-collected mid-turbinate nasal swab specimens from individuals aged 2 years or older with symptoms of COVID-19 within the first 7 days of symptom onset.

- The Ellume COVID-19 Home Test is also authorized for non-prescription home use with self-collected mid-turbinate nasal swab specimens from individuals aged 16 years or older, or adult-collected mid-turbinate nasal swab specimens from individuals aged 2 years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 when

Report adverse events, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home) or by calling 1-800-FDA-1088
tested twice over two to three days with at least 24 hours (and no more than 48 hours) between tests.

When collecting and handling specimens from individuals suspected of being infected with the virus that causes COVID-19, appropriate personal protective equipment should be used as outlined in the CDC Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19). For additional information, refer to CDC Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for Coronavirus Disease 2019 (COVID-19) (see links provided in “Where can I go for updates and more information?” section).

What does it mean if the specimen tests positive for the virus that causes COVID-19?

A positive test result for COVID-19 indicates that antigens from SARS-CoV-2 were detected, and the patient is very likely infected with the virus and presumed to be contagious. Test results should always be considered in the context of clinical observations and epidemiological data (such as local prevalence rates and current outbreak/epicenter locations) in making a final diagnosis and patient management decisions. Patient management should be made by a healthcare professional and follow current CDC guidelines.

The Ellume COVID-19 Home Test has been designed to minimize the likelihood of false positive test results. In the event of a false positive result, risks to patients could include the following: a recommendation for isolation of the patient, monitoring of household or other close contacts for symptoms, patient isolation that might limit contact with family or friends and may increase contact with other COVID-19 patients, limits in the ability to work, delayed diagnosis and treatment for the true cause of the symptoms, unnecessary prescription of a treatment or therapy, or other unintended adverse effects.

The Ellume COVID-19 Home Test Application automatically reports test results according to the reporting guidelines of appropriate public health authorities.

What does it mean if the specimen tests negative for the virus that causes COVID-19?

A negative test result for this test means that SARS-CoV-2 antigens were not present in the specimen above the limit of detection. However, a negative result does not rule out COVID-19 and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Antigen tests are known to be less sensitive than molecular tests that detect viral nucleic acids. The amount of antigen in a specimen may decrease as the duration of illness increases. As days post-symptom onset increase, antigen test results may be more likely to be negative compared to a molecular SARS-CoV-2 assay. Therefore, negative results are presumptive and confirmation with a molecular assay, if necessary for patient management, may be performed.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient’s recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. The possibility of a false negative result should especially be considered if the patient’s recent exposures or clinical presentation indicate that COVID-19 is likely, and diagnostic tests for other causes of illness (e.g., other respiratory illness) are negative. If COVID-19 is still suspected based on exposure history together with other clinical findings, re-testing or testing with molecular methods should be considered by healthcare professionals in consultation with public health authorities.

Risks to a patient of a false negative test result include: delayed or lack of supportive or definitive treatment, lack of monitoring of infected individuals and their household or other close contacts for symptoms resulting in increased risk of spread of COVID-19 within the community, or other unintended adverse events.

A negative antigen test should not be the sole basis used to determine if a patient can end isolation precautions. For additional recommendations regarding infection control, refer to CDC’s Discontinuation of Isolation for Persons with COVID-19 Not in Healthcare Settings (Interim Guidance) (see links provided in “Where can I go for updates and more information” section).

The performance of this test was established based on the evaluation of a limited number of clinical specimens collected between October 2020 and November 2020. The clinical performance has not been established in all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and
location of the clinical evaluation. Performance at the
time of testing may vary depending on the variants
circulating, including newly emerging strains of SARS-CoV-
2 and their prevalence, which change over time.

What do I need to know about serial testing in
asymptomatic individuals?

In asymptomatic individuals, serial testing may assist in
identifying infected individuals and facilitate timely
infection control practices. A negative test result does not
rule out infection but repeat testing over two or three
days with at least 24 hours (and no more than 48 hours)
between tests may decrease the risk of false negative
results.

Additional clinical studies are underway to assess the
performance of rapid antigen tests when used with serial
testing. An initial negative test result should be the first of
a minimum of two tests. An asymptomatic individual
undergoing serial testing with two or more negative
results may require ongoing serial testing or confirmatory
testing, depending on patient history and potential
exposures. An asymptomatic individual undergoing serial
testing with one or more positive results indicates that
SARS-CoV-2 antigen is present, but does not rule out
coinfection with other pathogens.

Additional confirmatory testing with a molecular test for
negative results may be necessary if there is a high
likelihood of SARS-CoV-2 infection, such as, an individual
with a close contact with COVID-19 or with suspected
exposure to COVID-19 or in communities with high
prevalence of infection. Additional confirmatory testing
with a molecular test for positive results may also be
necessary, if there is a low likelihood of SARS-CoV-2
infection, such as in individuals without known exposures
to SARS-CoV-2 or residing in communities with low
prevalence of infection. For additional recommendations
regarding confirmation of antigen test results, please
refer to the CDC’s Interim Guidance for Antigen Testing
for SARS-CoV-2 (see links provided in “Where can I go for
updates and more information?” section).

Where can I go for updates and more information?

CDC webpages:

General: https://www.cdc.gov/coronavirus/2019-
ncov/index.html
Symptoms: https://www.cdc.gov/coronavirus/2019-
ncov/symptoms-testing/symptoms.html
Healthcare Professionals:
https://www.cdc.gov/coronavirus/2019-
ncov/hcp/index.html
Isolation Precautions in Healthcare Settings:
https://www.cdc.gov/coronavirus/2019-
ncov/lab/guidelines-clinical-specimens.html
Specimen Collection:
https://www.cdc.gov/coronavirus/2019-
ncov/lab/guidelines-clinical-specimens.html
Infection Control:
https://www.cdc.gov/coronavirus/2019-
ncov/php/infection-control.html
Discontinuation of Isolation:
https://www.cdc.gov/coronavirus/2019-
ncov/hcp/disposition-in-home-patients.html
Influenza: https://www.cdc.gov/flu/index.htm
Antigen Tests: https://www.cdc.gov/coronavirus/2019-
nCoV/hcp/resources/antigen-tests-guidelines.html

What is an EUA?

The United States FDA has made this test available under
an emergency access mechanism called an Emergency
Use Authorization (EUA). The EUA is supported by the
Secretary of Health and Human Service’s (HHS’s)
declaration that circumstances exist to justify the
emergency use of in vitro diagnostics (IVDs) for the
detection and/or diagnosis of the virus that causes
COVID-19.

An IVD made available under an EUA has not undergone
the same type of review as an FDA-approved or cleared
IVD. FDA may issue an EUA when certain criteria are met,
which includes that there are no adequate, approved,
available alternatives, and based on the totality of
scientific evidence available, it is reasonable to believe
that this IVD may be effective in diagnosing COVID-19.

The EUA for this test is in effect for the duration of the
COVID-19 declaration justifying emergency use of IVDs,
unless it is terminated or revoked sooner (after which
the test may no longer be used).

What are the approved available alternatives?

There are no approved, available, alternative antigen
tests.

Any tests that have received full marketing status (e.g.,
cleared, approved), as opposed to an EUA, by FDA can be
found by searching the medical device databases here:
https://www.fda.gov/medical-devices/device-advice-
comprehensive-regulatory-assistance/medical-device-
databases.

A cleared or approved test should be used instead of a
test made available under an EUA, when appropriate and
available. FDA has issued EUAs for other tests that can be
found at: https://www.fda.gov/emergency-preparedness-
and-response/mcm-legal-regulatory-and-policy-
framework/emergency-use-authorization.

FDA webpages:
General: www.fda.gov/novelcoronavirus
EUAs: (includes links to patient fact sheet and
manufacturer’s instructions)
https://www.fda.gov/medical-devices/coronavirus-
disease-2019-covid-19-emergency-use-authorizations-
medical-devices/in-vitro-diagnostics-euas

Ellume Limited
57 Didsbury St, East Brisbane, QLD 4169, Australia

Customer Support phone number: 1-888-885-6121
www.ellumehealth.com

Report adverse events, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home) or by calling 1-800-FDA-1088